Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-06-27
2006-06-27
Andres, Janet L. (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009100, C435S041000, C435S088000
Reexamination Certificate
active
07067261
ABSTRACT:
The invention provides methods of screening for substances having an effect on a nicotine receptor by contacting a cell having a nicotine receptor with a test substance; and determining any increase or decrease in phosphorylation of Janus-Activated Kinase 2 (JAK2). An increase in phosphorylation of JAK2 indicates that the test substance stimulates the nicotine receptor, and wherein a decrease in phosphorylation of JAK2 indicates that the test substance inhibits the nicotine receptor. The invention also provides screening methods for identification of substances that affect nicotine receptor activity through activity mediated by the AT2 receptor. Related pharmaceutical compositions and methods of treatment are also provided.
REFERENCES:
patent: 4922901 (1990-05-01), Brooks et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5712270 (1998-01-01), Sabb
patent: 5837815 (1998-11-01), Lev et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 5986100 (1999-11-01), Crooks et al.
patent: 6057446 (2000-05-01), Crooks et al.
patent: 6211372 (2001-04-01), Crooks et al.
patent: 6218383 (2001-04-01), Bencherif
patent: 6232316 (2001-05-01), Dull et al.
patent: 6310102 (2001-10-01), Dull et al.
patent: 6376242 (2002-04-01), Hanson
patent: 6440681 (2002-08-01), Elliott et al.
patent: 6475753 (2002-11-01), Ruben et al.
patent: 2002/0052311 (2002-05-01), Solomon et al.
patent: WO 02/16357 (2002-02-01), None
patent: 1300407 (2003-04-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 99/62505 (1999-12-01), None
patent: WO 99/65876 (1999-12-01), None
patent: WO 00/07600 (2000-02-01), None
patent: WO 00/71520 (2000-11-01), None
patent: WO 01/36417 (2001-05-01), None
patent: WO 01/82978 (2001-11-01), None
patent: WO 01/90109 (2001-11-01), None
patent: WO 02/15662 (2002-02-01), None
patent: WO 02/16355 (2002-02-01), None
patent: WO 02/16356 (2002-02-01), None
patent: WO 02/16358 (2002-02-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 02/051841 (2002-07-01), None
McGreer and McGreer, Brain Research Rev. 21: 195-218, 1995.
Gattu et al., Brain Res. 771: 89-103, 1997.
Kajstura et al.b, J. Mol. Cell. Card. 29: 859-870, 1997.
Latchman, D., “Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues,”Pharmacology&Therapeutics, 85: 29-37 (2000).
Dineley, K., et al., “β-Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal α7 Nicotinic Acetylcholine Receptors:In VitroandIn VivoMechansims Related to Alzheimer's Disease,”J. Neurosci. 21(12):4125-4133 (Jun. 15, 2001).
International Search Report for PCT/US02/39952 mailed Jun. 11, 2003.
AbdAlla, S., et al., “The Angiotensin II AT2Receptor Is an AT1Receptor Antagonist,”J. Biol. Chem. 276 (43): 39721-39726 (Oct. 2001).
Akishita, M. et al., “Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth,”J. Clin. Invest. 103(1): 63-71 (1999).
Ali, M. S., et al., “Angiotensin II Stimulates Tyrosine Phosphorylation and Activation of Insulin Receptor Substrate 1 and Protein-tyrosine Phosphatase 1D in Vascular Smooth Muscle Cells,”J. Biol. Chem. 272(19):12373-12379 (1997).
Ali, M. S., et al., “Dependence on the Motif YIPP for the Physical Association of Jak2 Kinase with the Intracellular Carboxyl Tail of the Angiotensin II AT1Receptor,”J. Biol. Chem. 272(37):23382-23388 (1997).
Amiri, F., et al., “Hyperglycemia Enhances Angiotensin II-induced Janus-activated Kinase/STAT Signaling in Vascular Smooth Muscle Cells,”J. Biol. Chem. 274(45): 32382-32386 (1999).
Amiri, F. et al., “Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose,”Kidney Int. 61: 1605-1616 (2002).
Arneric, S., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev. 1(1): 1-26 (1995).
Arneric, S., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin Invest. Drugs5(1): 79-100 (1996).
Bannon, A. W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science279: 77-80 (1998).
Barnes, N. M., et al., “Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease,”Eur. J. Pharmacol200: 289-292 (1991).
Bencherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I.In VitroCharacterization,”J.P.E.T.279(3): 1413-1421 (1996).
Bencherif, M. and J. D. Schmitt, “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,”Current Drug Targets1 (4): 349-357 (2002).
Bencherif, M. and R. J. Lukas, “Vanadate amplifies receptor-mediated accumulation of inositol trisphosphates and inhibits inositol tris-and tetrakis-phosphatase activities,”Neurosci. Lett. 134: 157-160 (1992).
Bernstein, K. E., and M. B. Marrero, “The Importance of Tyrosine Phosphorylation in Angiotensin II Signaling,”Trends. Cardiovasc. Med. 6(6): 179-187 (1996).
Bhat, G. J., et al., “Angiotensin II Stimulates sis-Inducing Factor-like DNA Biding Activity”J. Biol. Chem. 269(50): 31443-31449 (1994).
Bhat, G. J., et al., “Activation of the STAT Pathway by Angiotensin II in T3CHO/AT1ACells,”j. Biol. Chem. 270(32): 19059-19065 (1995).
Breese, C.R. et al.“Comparison of the Regional Expression of Nicotinic Acetylcholine Receptor α7 mRNA and [125I]-α-Bungarotoxin Binding in Human Postmortem Brain,”J. Com. Neurol. 387: 385-398 (1997).
Brown, N.J. and D.E. Vaughan, “Angiotensin-Converting Enzyme Inhibitors,”Circulation97: 1411-1420 (1998).
Chamoux, E., et al., “The AT2 receptor of Angiotensin II and Apoptosis in Human Fetal Adrenal Gland,”Endocr. Res. 26(4): 955-957 (Nov. 2000).
Chini, B. et al., “Molecular Cloning and Chromosomal Localization of the Human α7-Nicotinic Receptor Subunit Gene (CHRNA7),”Genomics19: 379-381 (1994).
Cooper, S. T. and N. S. Millar, “Host Cell-Specific Folding and Assembly of the Neuronal Nicotinic Acetylcholine Receptor α7 Subunit,”J. Neurochem. 68(5): 2140-2151 (1997).
Court, J., et al., “Nicotinic Receptor Abnormalities in Alzheimer's Disease,”Biol. Psychiatry49:175-184 (Feb. 2001).
Cui, T. et al., “Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell,”Cardiovasc. Res. 49(4):863-871 (Mar. 2001).
Damaj, et al., “Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist,”Society for Neuroscience, 23: 669 ABSTRACT 266.9 (1997).
Darnell, J. E., Jr., et al., “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins,”Science264:1415-1421 (1994).
De Fiebre, C. M., et al., “Characterization of a Series of Anabaseine-Derived Compounds Reveals That the 3-(4)-Dimethylaminocinnamylidine Derivative is a Selective Agonist at Neuronal Nicotinic α7/125|-α-Bungarotoxin Receptor Subtypes,”Mol. Pharmacol. 47:164-171 (1995).
Digicaylioglu, M. and S. A. Lipton, “Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascades,”Nature412:641-647 (Aug. 2001).
Dolle, F., et al., “Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the α7 nicotinic acetylcholine receptor,”J. Labelled Cpd. Radiopharm. 44: 785-795 (2001).
Donnely-Reoberts, D.L. et al, “In vitro neuropro
Bencherif Merouane
Marrero Mario B.
Andres Janet L.
Chandra Gyan
Medical College of Georgia Research Institute Inc.
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Methods and compositions for treatment of central nervous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of central nervous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of central nervous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628083